MedTrace Logo

Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

NCT00280098 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-12-07

No results posted yet for this study

Summary

Evaluation of safety and efficacy of docetaxel in the treatment of advanced hormone refractory prostate cancer under the conditions of daily practise.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

docetaxel

Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid

Sponsors & Collaborators

Principal Investigators

  • Zuzana MD Priborska · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-10-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00280098 on ClinicalTrials.gov